



Our STN: BL 125737/0

MID-CYCLE COMMUNICATION SUMMARY
JUNE 29, 2021

VBI Vaccines (Delaware) Inc.
Attention: Norman W. Baylor, Ph.D.
Biologics Consulting Group, Inc. (Authorized U.S. Agent)
1555 King Street, Suite 300
Alexandria, VA 22314

Dear Dr. Baylor:

Attached is a copy of the summary of your May 25, 2021 Mid-Cycle Communication Teleconference with CBER. This memorandum constitutes the official record of the Teleconference. If your understanding of the Teleconference outcomes differs from those expressed in this summary, it is your responsibility to communicate with CBER as soon as possible.

Please include a reference to STN 125737/0 in your future submissions related to the subject product.

If you have any questions, please contact Katherine Berkhausen (email: Katherine.Berkhausen@fda.hhs.gov) or Paul Keller (email: Paul.Keller@fda.hhs.gov) at 301-796-2640.

Sincerely,

Loris D. McVittie, PhD
Deputy Director - Regulatory
Division of Viral Products and Related Product
Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research

Mid-Cycle Communication Teleconference Summary

Application type and number: BLA STN 125737/0
Product name: Hepatitis B Vaccine (Recombinant), 3-antigen
Proposed Indication: Prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years and older.
Applicant: VBI Vaccines (Delaware), Inc.
Meeting date & time: May 25, 2021 10:30 AM – 12:00 PM
Committee Chair: Marian Major, PhD
RPMs: Paul Keller, PhD
Katherine Berkhausen, RN BSN

FDA Attendees:

Sudhakar Agnihotram, PhD	OVRD/DVRPA
Noel Baichoo, PhD	OCBQ/DBSQC
Dennis Cato	OCBQ/DIS
Darcie Everett, MD, MPH	OVRD/DVRPA
Meghan Ferris, MD, MPH	OVRD/DVRPA
Doran Fink, MD, PhD	OVRD/DVRPA
Timothy Fritz, PhD	OVRD/DVRPA
Sara Gagneten	OVRD/DVP
Varsha Garnepudi, MS	OCBQ/DBSQC
Dave Green, PhD	OVRD/DVRPA
Marion Gruber, PhD	OVRD
Lei Huang, PhD	OBE/DE
Bhanu Kannan, PhD	OCBQ/DIS
Paul Keller, PhD	OVRD/DVRPA
Jennifer Kirk, PhD	OBE/DB
Hyesuk Kong, PhD	OCBQ/DBSQC
Philip Krause, MD	OVRD
Tsai-Lien Lin, PhD	OBE/DB
Anthony Lorenzo	OCBQ/DMPQ
Marian Major, PhD	OVRD/DVP
Rakesh Pandey, PhD	OVRD/DVRPA
Priscilla M. Pastrana	OCBQ/DMPQ
Twanda Scales	OCBQ/DCM
Lauren Siltz, PhD	OVRD/DVP
Daphne Stewart	OVRD/DVRPA
Lisa Stockbridge, PhD	OCBQ/DCM
Debra Vause, RN, BSN	OCBQ/DMPQ

Applicant Attendees:

Alka Chaudhari	VBI Vaccines
----------------	--------------

Francisco Diaz-Mitoma
Nathalie Machluf
Avi Mazaltov
Johanna Spaans
Vlad Popovic
Vince Narbut
Kelly Reich
Chris Vessely

VBI Vaccines
SciVac Ltd.
SciVac Ltd.
VBI Vaccines
VBI Vaccines
Biologics Consulting
Biologics Consulting
Biologics Consulting

Discussion Summary:

1. Any significant issues/major deficiencies, categorized by discipline, identified by the Review Committee to date.

There are no significant issues or major deficiencies identified at this time.

-There was no additional discussion of this item during the telecon.

2. Information regarding major safety concerns.

CBER does not have any major safety concerns identified at this time.

-There was no additional discussion of this item during the telecon.

3. Preliminary Review Committee thinking regarding risk management.

The review of the Risk Management Plan is ongoing.

-There was no additional discussion of this item during the telecon.

4. Any information requests sent and responses not received.

- a. Information request #3 (submitted on March 1, 2021, full response expected by July 1, 2021 - partial response received in Am #4)

-There was no additional discussion of this item during the telecon.

- b. Information request #6 (submitted on April 9, 2021, response expected by June 11).

-There was no additional discussion of this item during the telecon.

- c. Information request #10 (submitted May 10, 2021, response expected by May 24, 2021)

-The response to IR #10 was received on May 24, 2021, this IR is no longer outstanding.

5. Any new information requests to be communicated.

We anticipate forthcoming IRs regarding review and evaluation of the ISS safety data, immunogenicity assay methodology recently submitted by VBI, and (b) (4) detected in some drug substance batches. Any additional requests for information that arise during review will be communicated during the course of the review.

-There was no additional discussion of specific pending IRs during the telecon; however, the applicant asked if there were any sections of the BLA review that could now be considered complete. The RPM replied that all sections of the BLA continue to be reviewed in parallel and confirmed that additional IRs may be identified in any section as the review proceeds.

6. Proposed date(s) for the Late-Cycle meeting (LCM).

- a. *The Late Cycle Meeting Telcon is currently scheduled for Thursday, August 19, 2021 at 11:30 AM – 1:00 PM ET.*
- b. *We intend to send meeting materials to you by Mon. August 9, 2021, in advance of the LCM.*
- c. *If these timelines change, we will communicate updates to you during the course of the review.*

-There was no additional discussion of the proposed dates during the telecon.

7. Updates regarding plans for the AC meeting.

This BLA will not be brought to the VRBPAC.

-There was no additional discussion of this item during the telecon.

8. Other projected milestone dates for the remainder of the review cycle, including changes to previously communicated dates.

<i>Late cycle Meeting with VBI:</i>	<i>August 19, 2021</i>
<i>Labeling Comments to VBI:</i>	<i>October 31, 2021</i>
<i>Finalize LRP:</i>	<i>October 31, 2021</i>
<i>PMC/PMR Determination:</i>	<i>October 31, 2021</i>
<i>Action Due Date:</i>	<i>November 30, 2021</i>

-There was no additional discussion of these dates during the telecon.

Additional Discussion:

- **Ms. Reich inquired about the pre-licensure inspection, and if CBER had any updates on inspection status. Anthony Lorenzo (OCBQ/DMPQ MBR2 Chief) responded that we are following guidance from the US State Department; currently we are unable to travel to Israel to perform the inspection and cannot promise a date at this time.**
- **Ms. Reich asked about labeling, and whether any questions regarding packaging, distribution, and product roll-out should be deferred to when labeling discussions begin. Paul Keller (RPM) replied that, in general, yes, these questions will be handled at that time, but that if specific questions were already formulated they could be communicated at any time during review.**